Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...
The SEC has rebuffed a Bristol-Myers Squibb Co. campaign against a shareholder proposal urging it to scrap its diversity, ...
We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...
Top health care investment bankers say that large deals involving pharmaceutical and biotech companies are stalling as executives grapple with ...
BMS says it is combining AI and machine learning with its researchers’ expertise in drug targets and mechanisms of action, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback